Table 3.

Influenza incidence as the primary endpoint, sub-grouped according to factors ¹.

	KB290 + βC	Placebo	RR	95% CI	p-Value
Sex
Female	16/570 (2.8%)	20/571 (3.5%)	0.796	0.408; 1.552	0.50
Male	15/510 (2.9%)	16/497 (3.2%)	0.911	0.445; 1.863	0.80
Age
˂40 years	10/539 (1.9%)	21/538 (3.9%)	0.465	0.217; 0.998	0.044
≥40 years	21/541 (3.9%)	15/530 (2.8%)	1.387	0.707; 2.720	0.34
Region
Hokkaido	9/360 (2.5%)	16/360 (4.4%)	0.551	0.240; 1.264	0.15
Kanto	13/360 (3.6%)	12/359 (3.3%)	1.083	0.487; 2.408	0.84
Kyushu	9/360 (2.5%)	8/349 (2.3%)	1.093	0.417; 2.866	0.86
Influenza vaccination status
Vaccinated	15/434 (3.5%)	12/459 (2.6%)	1.334	0.617; 2.882	0.46
Unvaccinated	16/646 (2.5%)	24/609 (3.9%)	0.619	0.326; 1.177	0.15

¹ Values in “influenza incidence” are expressed as incidence/total number of subjects. The percent sign (%) indicates the rate of influenza incidence.